DK2281042T3 - Mikrokuglebaseret sammensætning til forebyggelse og/eller ophævelse af begyndende autoimmun diabetes - Google Patents
Mikrokuglebaseret sammensætning til forebyggelse og/eller ophævelse af begyndende autoimmun diabetes Download PDFInfo
- Publication number
- DK2281042T3 DK2281042T3 DK09732817.3T DK09732817T DK2281042T3 DK 2281042 T3 DK2281042 T3 DK 2281042T3 DK 09732817 T DK09732817 T DK 09732817T DK 2281042 T3 DK2281042 T3 DK 2281042T3
- Authority
- DK
- Denmark
- Prior art keywords
- seq
- human
- oligonucleotides
- microspheres
- diabetes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Claims (13)
1. Farmaceutisk sammensætning omfattende: (i) et antisense-oligonukleotid, som er SEQ ID NO: 4, eller et antisense- 5 oligonukleotid, som har mindst 90% polynukleotidsekvenshomologi med SEQ ID NO: 4, som er rettet mod det humane primære CD40-transkript og binder sig til dette, (ii) et antisense-oligonukleotid, som er SEQ ID NO: 6, eller et antisense-oligonukleotid, som har mindst 90% polynukleotidsekvenshomologi med SEQ 10 ID NO: 6, som er rettet mod det humane primære CD86-transkript og binder sig til dette, og (iii) et antisense-oligonukleotid, som er SEQ ID NO: 7, eller et antisense-oligonukleotid, som har mindst 90% polynukleotidsekvenshomologi med SEQ ID NO: 7, og som er rettet mod det humane primære CD80-transkript og binder 15 sig til dette, idet oligonukleotiderne er formuleret i mikrokugler.
2. Farmaceutisk sammensætning ifølge krav 1, hvori hvert enkelt af antisense-oligonukleotiderne har mindst 95% polynukleotidsekvenshomologi med en vilkårlig af SEQ ID NO: 4, SEQ ID NO: 6 eller SEQ ID NO: 7. 20
3. Farmaceutisk sammensætning ifølge krav 1 eller krav 2, hvori mindst 70 vægt% af mikrokuglerne er oligonukleotider, eventuelt hvori forholdet mellem de enkelte antisense-oligonukleotider i sammensætningen CD40-antisense/CD80-antisense/-CD86-antisense er 1:1:1. 25
4. Farmaceutisk sammensætning ifølge krav 1 eller krav 2, hvori sammensætningen omfatter antisense-oligonukleotider, der hvert især omfatter polynukleotidsekvenserne SEQ ID NO: 4, SEQ ID NO: 6 og SEQ ID NO: 7.
5. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 1 til 4 til anvendelse ved behandling af en sygdom eller en lidelse i et menneske.
6. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 1 til 4 til anvendelse ved behandling af diabetes type 1 i et menneske, idet sammensætningen 35 indgives før eller efter klinisk indtræden af diabetes type 1.
7. Farmaceutisk sammensætning ifølge krav 5 eller 6 til anvendelse ved normalisering af blodglucoseniveauer i det pågældende menneske i sammenligning med menneskets blodglucoseniveauer inden indgivelsen.
8. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 5 til 7 til anvendelse ved regenerering af det pågældende menneskes betacellebestand.
9. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 5 til 7 til anvendelse ved bevaring af resterende betacellemasse i et menneske, idet menneskets 10 betacellemasse ved anvendelse af sammensætningen opretholdes på mindst ca. 15% af den før indtræden af diabetes tilstedeværende masse, eller til anvendelse ved behandling eller ophævelse af diabetes type 1 i et menneske eller til anvendelse ved beskyttelse af betaceller i et menneskes pankreas eller til anvendelse ved nedsættelse af T-celleformidlet pankreasinflammation eller pankreascelledød i et menneske. 15
10. Farmaceutisk sammensætning ifølge et hvilket som helst af kravene 5 til 9, hvor sammensætningen indgives i kombination med insulin, eventuelt hvor insulin indgives før, samtidig med eller efter indgivelse af sammensætningen.
11. Farmaceutisk sammensætning ifølge et hvilket som helst af de foregående krav, hvor sammensætningen indgives som en injicerbar form.
12. Farmaceutisk sammensætning ifølge et hvilket som helst af de foregående krav, hvor sammensætningen er formuleret til gentagen indgivelse. 25
13. Anvendelse af den farmaceutiske sammensætning ifølge et hvilket som helst af kravene 1 til 4 ved fremstilling af et medikament til behandling af diabetes type 1 i et menneske, idet sammensætningen indgives før eller efter klinisk indtræden af diabetes type 1. 30
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4603408P | 2008-04-18 | 2008-04-18 | |
US4824608P | 2008-04-28 | 2008-04-28 | |
PCT/US2009/041167 WO2009129544A1 (en) | 2008-04-18 | 2009-04-20 | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2281042T3 true DK2281042T3 (da) | 2015-11-09 |
Family
ID=40941866
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09732817.3T DK2281042T3 (da) | 2008-04-18 | 2009-04-20 | Mikrokuglebaseret sammensætning til forebyggelse og/eller ophævelse af begyndende autoimmun diabetes |
DK15174152.7T DK2982753T3 (da) | 2008-04-18 | 2009-04-20 | Mikrosfære-baseret sammensætning til at forebygge og/eller reversere nystartet autoimmun diabetes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15174152.7T DK2982753T3 (da) | 2008-04-18 | 2009-04-20 | Mikrosfære-baseret sammensætning til at forebygge og/eller reversere nystartet autoimmun diabetes |
Country Status (12)
Country | Link |
---|---|
US (1) | US8022046B2 (da) |
EP (2) | EP2982753B1 (da) |
JP (4) | JP5685182B2 (da) |
CN (1) | CN102007213B (da) |
AU (1) | AU2009237577B2 (da) |
CA (1) | CA2720675C (da) |
DK (2) | DK2281042T3 (da) |
ES (2) | ES2554168T3 (da) |
HK (1) | HK1221261A1 (da) |
MX (1) | MX2010011508A (da) |
PL (2) | PL2281042T3 (da) |
WO (1) | WO2009129544A1 (da) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2982753B1 (en) * | 2008-04-18 | 2018-06-06 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
US9072766B2 (en) | 2010-11-18 | 2015-07-07 | Beth Israel Deaconess Medical Center, Inc. | Methods of treating obesity by inhibiting nicotinamide N-methyl transferase (NNMT) |
JP6348484B2 (ja) * | 2012-04-18 | 2018-06-27 | ノグラ ファーマ リミテッド | 糖尿病を処置する方法および/または移植後の膵島の生存を促進する方法 |
AU2014348184B2 (en) * | 2013-11-18 | 2020-08-27 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies |
PL424035A1 (pl) | 2015-06-30 | 2019-01-02 | Northwest Biotherapeutics, Inc. | Optymalnie aktywowane komórki dendrytyczne, które indukują ulepszoną lub zwiększoną przeciwnowotworową odpowiedź odpornościową |
Family Cites Families (126)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
US4469863A (en) | 1980-11-12 | 1984-09-04 | Ts O Paul O P | Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof |
US5023243A (en) | 1981-10-23 | 1991-06-11 | Molecular Biosystems, Inc. | Oligonucleotide therapeutic agent and method of making same |
US4476301A (en) | 1982-04-29 | 1984-10-09 | Centre National De La Recherche Scientifique | Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US5118800A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | Oligonucleotides possessing a primary amino group in the terminal nucleotide |
US5417986A (en) | 1984-03-16 | 1995-05-23 | The United States Of America As Represented By The Secretary Of The Army | Vaccines against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres |
US5550111A (en) | 1984-07-11 | 1996-08-27 | Temple University-Of The Commonwealth System Of Higher Education | Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof |
FR2567892B1 (fr) | 1984-07-19 | 1989-02-17 | Centre Nat Rech Scient | Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons |
US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
US5405938A (en) | 1989-12-20 | 1995-04-11 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US5185444A (en) | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5166315A (en) | 1989-12-20 | 1992-11-24 | Anti-Gene Development Group | Sequence-specific binding polymers for duplex nucleic acids |
US5102872A (en) | 1985-09-20 | 1992-04-07 | Cetus Corporation | Controlled-release formulations of interleukin-2 |
GB8601100D0 (en) | 1986-01-17 | 1986-02-19 | Cosmas Damian Ltd | Drug delivery system |
EP0248531A3 (en) | 1986-05-02 | 1988-09-28 | Southern Research Institute | Encapsulated nucleic acids |
ES2053549T3 (es) | 1986-08-11 | 1994-08-01 | Innovata Biomed Ltd | Un proceso para la preparacion de una formulacion farmaceutica apropiada para inhalacion. |
US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US5276019A (en) | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
JP2828642B2 (ja) | 1987-06-24 | 1998-11-25 | ハワード フローレイ インスティテュト オブ イクスペリメンタル フィジオロジー アンド メディシン | ヌクレオシド誘導体 |
US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
US4924624A (en) | 1987-10-22 | 1990-05-15 | Temple University-Of The Commonwealth System Of Higher Education | 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof |
US5188897A (en) | 1987-10-22 | 1993-02-23 | Temple University Of The Commonwealth System Of Higher Education | Encapsulated 2',5'-phosphorothioate oligoadenylates |
JPH03503894A (ja) | 1988-03-25 | 1991-08-29 | ユニバーシィティ オブ バージニア アランミ パテンツ ファウンデイション | オリゴヌクレオチド n‐アルキルホスホラミデート |
US5278302A (en) | 1988-05-26 | 1994-01-11 | University Patents, Inc. | Polynucleotide phosphorodithioates |
US5216141A (en) | 1988-06-06 | 1993-06-01 | Benner Steven A | Oligonucleotide analogs containing sulfur linkages |
US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
US5194599A (en) | 1988-09-23 | 1993-03-16 | Gilead Sciences, Inc. | Hydrogen phosphonodithioate compositions |
US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
US5591722A (en) | 1989-09-15 | 1997-01-07 | Southern Research Institute | 2'-deoxy-4'-thioribonucleosides and their antiviral activity |
US5721218A (en) | 1989-10-23 | 1998-02-24 | Gilead Sciences, Inc. | Oligonucleotides with inverted polarity |
US5399676A (en) | 1989-10-23 | 1995-03-21 | Gilead Sciences | Oligonucleotides with inverted polarity |
EP0942000B1 (en) | 1989-10-24 | 2004-06-23 | Isis Pharmaceuticals, Inc. | 2'-Modified oligonucleotides |
US5264562A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
US5264564A (en) | 1989-10-24 | 1993-11-23 | Gilead Sciences | Oligonucleotide analogs with novel linkages |
US5177198A (en) | 1989-11-30 | 1993-01-05 | University Of N.C. At Chapel Hill | Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates |
US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
US5646265A (en) | 1990-01-11 | 1997-07-08 | Isis Pharmceuticals, Inc. | Process for the preparation of 2'-O-alkyl purine phosphoramidites |
US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
US5321131A (en) | 1990-03-08 | 1994-06-14 | Hybridon, Inc. | Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling |
US5470967A (en) | 1990-04-10 | 1995-11-28 | The Dupont Merck Pharmaceutical Company | Oligonucleotide analogs with sulfamate linkages |
GB9009980D0 (en) | 1990-05-03 | 1990-06-27 | Amersham Int Plc | Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides |
ES2116977T3 (es) | 1990-05-11 | 1998-08-01 | Microprobe Corp | Soportes solidos para ensayos de hibridacion de acidos nucleicos y metodos para inmovilizar oligonucleotidos de modo covalente. |
JP3359919B2 (ja) | 1990-05-16 | 2002-12-24 | サザン・リサーチ・インスティテュート | 放出制御ドーパミンおよび神経線維成長を刺激するための用途 |
US5602240A (en) | 1990-07-27 | 1997-02-11 | Ciba Geigy Ag. | Backbone modified oligonucleotide analogs |
US5677437A (en) | 1990-07-27 | 1997-10-14 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
BR9106702A (pt) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals Inc | Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo |
US5489677A (en) | 1990-07-27 | 1996-02-06 | Isis Pharmaceuticals, Inc. | Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms |
US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
US5623070A (en) | 1990-07-27 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Heteroatomic oligonucleoside linkages |
US5618704A (en) | 1990-07-27 | 1997-04-08 | Isis Pharmacueticals, Inc. | Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling |
US5610289A (en) | 1990-07-27 | 1997-03-11 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogues |
US5541307A (en) | 1990-07-27 | 1996-07-30 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs and solid phase synthesis thereof |
GB9016885D0 (en) | 1990-08-01 | 1990-09-12 | Scras | Sustained release pharmaceutical compositions |
IL113519A (en) | 1990-08-03 | 1997-11-20 | Sterling Winthrop Inc | Oligonucleoside sequences of from about 6 to about 200 bases having a three atom internucleoside linkage, their preparation and pharmaceutical compositions for inhibiting gene expression containing said oligonucleosides |
US5177196A (en) | 1990-08-16 | 1993-01-05 | Microprobe Corporation | Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof |
HU206372B (en) | 1990-09-03 | 1992-10-28 | Richter Gedeon Vegyeszet | Process for producing new oligopeptides which selectively inhibit proliferation of haemopoietic cells and pharmaceutical compositions comprising same |
US5214134A (en) | 1990-09-12 | 1993-05-25 | Sterling Winthrop Inc. | Process of linking nucleosides with a siloxane bridge |
US5561225A (en) | 1990-09-19 | 1996-10-01 | Southern Research Institute | Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages |
CA2092002A1 (en) | 1990-09-20 | 1992-03-21 | Mark Matteucci | Modified internucleoside linkages |
US5149543A (en) | 1990-10-05 | 1992-09-22 | Massachusetts Institute Of Technology | Ionically cross-linked polymeric microcapsules |
US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
US5672697A (en) | 1991-02-08 | 1997-09-30 | Gilead Sciences, Inc. | Nucleoside 5'-methylene phosphonates |
US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
US5714331A (en) | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5719262A (en) | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5571799A (en) | 1991-08-12 | 1996-11-05 | Basco, Ltd. | (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response |
DE59208572D1 (de) | 1991-10-17 | 1997-07-10 | Ciba Geigy Ag | Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte |
US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
JP3739785B2 (ja) | 1991-11-26 | 2006-01-25 | アイシス ファーマシューティカルズ,インコーポレイティド | 修飾されたピリミジンを含有するオリゴマーを使用する増強された三重らせんおよび二重らせんの成形 |
US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
US5792608A (en) | 1991-12-12 | 1998-08-11 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
US5359044A (en) | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US5525519A (en) | 1992-01-07 | 1996-06-11 | Middlesex Sciences, Inc. | Method for isolating biomolecules from a biological sample with linear polymers |
FR2687679B1 (fr) | 1992-02-05 | 1994-10-28 | Centre Nat Rech Scient | Oligothionucleotides. |
JPH05234332A (ja) | 1992-02-18 | 1993-09-10 | Sony Corp | ディスク再生装置 |
US5633360A (en) | 1992-04-14 | 1997-05-27 | Gilead Sciences, Inc. | Oligonucleotide analogs capable of passive cell membrane permeation |
US5434257A (en) | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
EP0577558A2 (de) | 1992-07-01 | 1994-01-05 | Ciba-Geigy Ag | Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte |
US5476925A (en) | 1993-02-01 | 1995-12-19 | Northwestern University | Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups |
GB9304618D0 (en) | 1993-03-06 | 1993-04-21 | Ciba Geigy Ag | Chemical compounds |
US6090925A (en) | 1993-03-09 | 2000-07-18 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5981719A (en) | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
ATE258685T1 (de) | 1993-03-09 | 2004-02-15 | Baxter Int | Makromolekulare mikropartikel und verfahren zur ihrer herstellung |
CA2159631A1 (en) | 1993-03-30 | 1994-10-13 | Sanofi | Acyclic nucleoside analogs and oligonucleotide sequences containing them |
WO1994022891A1 (en) | 1993-03-31 | 1994-10-13 | Sterling Winthrop Inc. | Oligonucleotides with amide linkages replacing phosphodiester linkages |
DE4311944A1 (de) | 1993-04-10 | 1994-10-13 | Degussa | Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen |
US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
US5446137B1 (en) | 1993-12-09 | 1998-10-06 | Behringwerke Ag | Oligonucleotides containing 4'-substituted nucleotides |
US5519134A (en) | 1994-01-11 | 1996-05-21 | Isis Pharmaceuticals, Inc. | Pyrrolidine-containing monomers and oligomers |
US6218510B1 (en) * | 1994-03-02 | 2001-04-17 | Brigham & Woman's Hospital | B7-1 and B7-2 polypeptides |
US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
US5627053A (en) | 1994-03-29 | 1997-05-06 | Ribozyme Pharmaceuticals, Inc. | 2'deoxy-2'-alkylnucleotide containing nucleic acid |
US5625050A (en) | 1994-03-31 | 1997-04-29 | Amgen Inc. | Modified oligonucleotides and intermediates useful in nucleic acid therapeutics |
US5646269A (en) | 1994-04-28 | 1997-07-08 | Gilead Sciences, Inc. | Method for oligonucleotide analog synthesis |
US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
US5597909A (en) | 1994-08-25 | 1997-01-28 | Chiron Corporation | Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use |
US5792747A (en) | 1995-01-24 | 1998-08-11 | The Administrators Of The Tulane Educational Fund | Highly potent agonists of growth hormone releasing hormone |
US5912340A (en) | 1995-10-04 | 1999-06-15 | Epoch Pharmaceuticals, Inc. | Selective binding complementary oligonucleotides |
US6319906B1 (en) * | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
IL135000A0 (en) | 1997-09-12 | 2001-05-20 | Exiqon As | Bi- and tri-cyclic nucleoside, nucleotide and oligonucleotide analogues |
AU768656B2 (en) * | 1998-04-17 | 2003-12-18 | University Of Vermont And State Agricultural College, The | Methods and products related to metabolic interactions in disease |
SE516700C2 (sv) * | 1999-06-07 | 2002-02-12 | Firefly Ab | Detektorarrangemang |
EP1072679A3 (en) | 1999-07-20 | 2002-07-31 | Agilent Technologies, Inc. (a Delaware corporation) | Method of producing nucleic acid molecules with reduced secondary structure |
US6458387B1 (en) | 1999-10-18 | 2002-10-01 | Epic Therapeutics, Inc. | Sustained release microspheres |
GB0207440D0 (en) * | 2002-03-28 | 2002-05-08 | Ppl Therapeutics Scotland Ltd | Tolerogenic antigen-presenting cells |
US20040219565A1 (en) | 2002-10-21 | 2004-11-04 | Sakari Kauppinen | Oligonucleotides useful for detecting and analyzing nucleic acids of interest |
WO2005105840A2 (en) * | 2004-03-26 | 2005-11-10 | Five Prime Therapeutics, Inc. | Cd40 variants and uses thereof |
WO2005112885A2 (en) * | 2004-05-12 | 2005-12-01 | Baxter International Inc. | Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1 |
EP1765294B1 (en) * | 2004-05-12 | 2008-09-24 | Baxter International Inc. | Nucleic acid microspheres, production and delivery thereof |
CN1980640A (zh) * | 2004-05-12 | 2007-06-13 | 巴克斯特国际公司 | 核酸微球体,其制备和递送 |
WO2005118788A2 (en) * | 2004-05-27 | 2005-12-15 | The Trustees Of The University Of Pennsylvania | Novel artificial antigen presenting cells and uses therefor |
MX2009001226A (es) * | 2006-08-04 | 2009-03-20 | Baxter Int | Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio. |
WO2008109495A2 (en) * | 2007-03-02 | 2008-09-12 | Mdrna, Inc. | Nucleic acid compounds for inhibiting cd40 gene expression and uses thereof |
EP2982753B1 (en) * | 2008-04-18 | 2018-06-06 | Baxter International Inc. | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |
-
2009
- 2009-04-20 EP EP15174152.7A patent/EP2982753B1/en active Active
- 2009-04-20 WO PCT/US2009/041167 patent/WO2009129544A1/en active Application Filing
- 2009-04-20 ES ES09732817.3T patent/ES2554168T3/es active Active
- 2009-04-20 ES ES15174152.7T patent/ES2686708T3/es active Active
- 2009-04-20 US US12/426,904 patent/US8022046B2/en not_active Expired - Fee Related
- 2009-04-20 PL PL09732817T patent/PL2281042T3/pl unknown
- 2009-04-20 DK DK09732817.3T patent/DK2281042T3/da active
- 2009-04-20 DK DK15174152.7T patent/DK2982753T3/da active
- 2009-04-20 JP JP2011505257A patent/JP5685182B2/ja not_active Expired - Fee Related
- 2009-04-20 MX MX2010011508A patent/MX2010011508A/es active IP Right Grant
- 2009-04-20 EP EP09732817.3A patent/EP2281042B1/en active Active
- 2009-04-20 PL PL15174152T patent/PL2982753T3/pl unknown
- 2009-04-20 AU AU2009237577A patent/AU2009237577B2/en active Active
- 2009-04-20 CN CN200980113547.XA patent/CN102007213B/zh active Active
- 2009-04-20 CA CA2720675A patent/CA2720675C/en active Active
-
2014
- 2014-10-10 JP JP2014208623A patent/JP2015007133A/ja not_active Withdrawn
-
2016
- 2016-08-09 HK HK16109472.0A patent/HK1221261A1/zh not_active IP Right Cessation
- 2016-11-14 JP JP2016221840A patent/JP2017036334A/ja not_active Withdrawn
-
2018
- 2018-09-21 JP JP2018177118A patent/JP2018197274A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2720675A1 (en) | 2009-10-22 |
JP2015007133A (ja) | 2015-01-15 |
CN102007213A (zh) | 2011-04-06 |
PL2281042T3 (pl) | 2016-01-29 |
PL2982753T3 (pl) | 2019-03-29 |
JP2018197274A (ja) | 2018-12-13 |
MX2010011508A (es) | 2011-05-03 |
EP2982753A1 (en) | 2016-02-10 |
JP2011519365A (ja) | 2011-07-07 |
EP2982753B1 (en) | 2018-06-06 |
AU2009237577A1 (en) | 2009-10-22 |
ES2554168T3 (es) | 2015-12-16 |
CA2720675C (en) | 2019-08-27 |
EP2281042A1 (en) | 2011-02-09 |
ES2686708T3 (es) | 2018-10-19 |
DK2982753T3 (da) | 2018-09-03 |
EP2281042B1 (en) | 2015-08-26 |
WO2009129544A1 (en) | 2009-10-22 |
CN102007213B (zh) | 2014-08-06 |
JP5685182B2 (ja) | 2015-03-18 |
JP2017036334A (ja) | 2017-02-16 |
US20090291145A1 (en) | 2009-11-26 |
HK1221261A1 (zh) | 2017-05-26 |
US8022046B2 (en) | 2011-09-20 |
AU2009237577B2 (en) | 2014-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018197274A (ja) | 初発自己免疫性糖尿病を予防するため、および/または逆転させるためのマイクロスフェアに基づく組成物 | |
MXPA06012990A (es) | Microesferas de acidos nucleicos, produccion y suministro de las mismas. | |
US8389493B2 (en) | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes | |
US20210401884A1 (en) | Microsphere-based delivery and ex vivo manipulation of dendritic cells for autoimmune therapies | |
AU2013213750B2 (en) | Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes |